# Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

> **NCT06284122** · PHASE3 · RECRUITING · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 790 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab
- **DRUG:** Obinutuzumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristin
- **DRUG:** Prednisone
- **DRUG:** Rituximab
- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustin

## Key facts

- **NCT ID:** NCT06284122
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-07
- **Primary completion:** 2028-11
- **Final completion:** 2034-04
- **Target enrollment:** 790 (ESTIMATED)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06284122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06284122, "Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06284122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*